Moderna Inc. said that it is developing a single-jab vaccine that combines an experimental flu shot, an RSV shot, and a booster dose for COVID-19.
Reuters reported that Moderna Chief Executive Officer Stéphane Bancel said in a presentation to update investors regarding the experimental drugs, “We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster. We believe Moderna could be first to market in this important new opportunity.”
Moderna’s latest vaccine contained the COVID-19 vaccine along with a nearly-finished influenza experimental shot. It also provided an update that its ongoing study now experiments with a 50-microgram shot to be used in a pediatric trial.
Oppenheimer & Co analyst Hartaj Singh said investors were positively surprised with the news that combination vaccine experiments will begin in the next six to 12 months.
Analysts said in August that Moderna, along with Pfizer Inc. and German partner BioNTech SE could garner billions of dollars from booster jabs, and profits might increase once the drug giants combine their COVID vaccine with jabs for influenza and other diseases.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.